80% ORR reported in injected tumours in Stage 1 of Ph 2a trial of tigilanol tiglate for Soft Tissue Sarcoma
QBiotics’ CEO and Managing Director, Stephen Doyle commented, “We are delighted with the outcomes from Stage 1 of our Phase IIa Soft Tissue Sarcoma trial. Tigilanol tiglate met both its primary and secondary endpoints and delivered patients an impressive 80% Objective Response Rate in injected tumours. Importantly, none of the 14 fully ablated (destroyed) tumours had recurred by the 6-month follow-up period, suggesting tigilanol tiglate may provide long-term benefit for patients. Given soft tissue sarcoma is a challenging cancer to treat, achieving this level of clinical activity is highly encouraging.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data